Literature DB >> 15622450

Monitoring of CD4+ and CD8+ T-cell responses after dendritic cell-based immunotherapy using CFSE dye dilution analysis.

Thomas Putz1, Reinhold Ramoner, Hubert Gander, Andrea Rahm, Georg Bartsch, Lorenz Höltl, Martin Thurnher.   

Abstract

CFSE dye dilution analysis and [3H] thymidine incorporation were used side by side to assess proliferative responses of peripheral blood mononuclear cells (PBMCs) after vaccination of renal cell carcinoma patients (n=6) with antigen-loaded dendritic cells. Immune responses against the control antigen keyhole limpet hemocyanin (KLH) were induced in all patients. While [3H] thymidine incorporation revealed a 4 to 977-fold increase in KLH-induced proliferation (mean: 209-fold), CFSE-labeling experiments demonstrated that the KLH-responsive population of postvaccination PBMCs represented 7-53% (mean: 23%). Combining CFSE-labeling with T-cell subset analysis confirmed the presence of CD4+ KLH-reactive T cells but also revealed a substantial population of CD8+ KLH-reactive T cells in one patient as well as minor populations of CD8+ KLH-reactive T cells in three other patients. Our data indicate that CFSE dye dilution analysis is a valuable tool for immune monitoring after dendritic cell vaccination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15622450     DOI: 10.1007/s10875-004-6237-2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  22 in total

1.  A role for IL-5 in the induction of cytotoxic T lymphocytes in vivo.

Authors:  V Apostolopoulos; I F McKenzie; C Lees; K I Matthaei; I G Young
Journal:  Eur J Immunol       Date:  2000-06       Impact factor: 5.532

2.  Immune monitoring in xenotransplantation: the multiparameter flow cytometric mixed lymphocyte culture assay.

Authors:  S H Popma; A M Krasinskas; A D McLean; W Y Szeto; D Kreisel; J S Moore; B R Rosengard
Journal:  Cytometry       Date:  2000-10-15

3.  Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma.

Authors:  C Rieser; R Ramoner; L Höltl; H Rogatsch; C Papesh; A Stenzl; G Bartsch; M Thurnher
Journal:  Urol Int       Date:  1999       Impact factor: 2.089

4.  Carboxyfluorescein succinimidyl ester-based proliferative assays for assessment of T cell function in the diagnostic laboratory.

Authors:  D Fulcher; S Wong
Journal:  Immunol Cell Biol       Date:  1999-12       Impact factor: 5.126

5.  Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells.

Authors:  Lorenz Höltl; Claudia Zelle-Rieser; Hubert Gander; Christine Papesh; Reinhold Ramoner; Georg Bartsch; Hermann Rogatsch; Adel L Barsoum; Joseph H Coggin; Martin Thurnher
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

6.  Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma.

Authors:  A Karolina Palucka; Madhav V Dhodapkar; Sophie Paczesny; Susan Burkeholder; Knut M Wittkowski; Ralph M Steinman; Joseph Fay; Jacques Banchereau
Journal:  J Immunother       Date:  2003 Sep-Oct       Impact factor: 4.456

7.  A sensitive method for detecting proliferation of rare autoantigen-specific human T cells.

Authors:  Stuart I Mannering; Jessica S Morris; Kent P Jensen; Anthony W Purcell; Margo C Honeyman; Peter M van Endert; Leonard C Harrison
Journal:  J Immunol Methods       Date:  2003-12       Impact factor: 2.303

8.  Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen.

Authors:  Michel Gilliet; Martin Kleinhans; Erica Lantelme; Dirk Schadendorf; Günter Burg; Frank O Nestle
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

Review 9.  The use of dendritic cells in cancer immunotherapy.

Authors:  Gerold Schuler; Beatrice Schuler-Thurner; Ralph M Steinman
Journal:  Curr Opin Immunol       Date:  2003-04       Impact factor: 7.486

10.  Interleukin 5 is a differentiation factor for cytotoxic T lymphocytes.

Authors:  T Ramos
Journal:  Immunol Lett       Date:  1989-06-15       Impact factor: 3.685

View more
  3 in total

1.  Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.

Authors:  Marina Zafranskaya; Patrick Oschmann; Rosel Engel; Andreas Weishaupt; Johannes M van Noort; Hassan Jomaa; Matthias Eberl
Journal:  Immunology       Date:  2006-12-18       Impact factor: 7.397

2.  Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer.

Authors:  Mayu O Frank; Julia Kaufman; Suyan Tian; Mayte Suárez-Fariñas; Salina Parveen; Nathalie E Blachère; Michael J Morris; Susan Slovin; Howard I Scher; Matthew L Albert; Robert B Darnell
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

Review 3.  Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.

Authors:  Andreas Draube; Nela Klein-González; Stefanie Mattheus; Corinne Brillant; Martin Hellmich; Andreas Engert; Michael von Bergwelt-Baildon
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.